NCT02377999 2025-02-24
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
Phase 2 Completed
Clinical Trials
12 trialsNCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT02462187 2023-04-06
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Novan, Inc.
Phase 2 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT03935204 2021-04-08
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01796821 2020-02-05
Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
G&E Herbal Biotechnology Co., LTD
Phase 2 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT02015260 2017-05-03
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
University of Aberdeen
Phase 2 Completed
NCT02849262 2017-03-31
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
Maruho Co., Ltd.
Phase 2 Completed
NCT00520598 2015-11-26
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00551187 2015-06-08
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed